A Phase 1 interventional study of AZD2373 subcutaneous injection and Placebo in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-10.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.
This study will be conducted as a single-centre, randomised, placebo-controlled, single-blind study to assess the effect of AZD2373 following ascending dose sequential group design administrations to healthy male subjects of African ancestry. The study will include 6 single dose cohorts with the option to include 2 additional cohorts based on emerging data from preceding cohorts in the study.
Approximately 48 male subjects aged 18 to 55 years at the time of informed consent (inclusive) will be randomized with the aim to have 8 subjects participate in each cohort. Within each cohort, 6 subjects will receive AZD2373 and 2 subjects will receive placebo.
Sentinel dosing will be applied for each cohort and will be divided into 2 groups:
The study will comprise:
The visit occurring at 5 weeks post dose (Visit 5) is optional. The expected duration for any subject participating in the study is approximately 10 weeks (excluding an up to 28-day Screening Period).
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any laboratory values with the following deviations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
Drug: AZD2373 subcutaneous injection · Drug: Placebo
Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
Number of subjects with adverse events and/or abnormal findings in vital signs, and/or clinical laboratory assessments and/or physical examination and/or electrocardiogram (ECG) evaluation and/or telemetry and/or injection site reactions
To assess adverse events as a variable of safety and tolerability of subcutaneous (SC) single ascending dose (SAD) administrations of AZD2373
Time frame: Screening Visit to final Follow-up Visit (Week 10 post last dose)
Area under plasma concentration-time curve from time zero extrapolated to infinity (AUC)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Area under the plasma concentration curve from time zero to the time of last quantifiable analyte concentration (AUClast)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Area under the plasma concentration-time curve from time zero to 72 hours after dosing [AUC(0-72)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Area under the plasma concentration-time curve from time zero to 48 hours after dosing [AUC (0-48)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Observed maximum plasma concentration (Cmax)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Time to reach peak or maximum observed concentration or response following drug administration (tmax)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Half-life associated with terminal slope (λz) of a semi logarithmic concentration-time curve (t½λz)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Apparent total body clearance of drug from plasma after extravascular administration [CL/F]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Mean residence time of the unchanged drug in the systemic circulation (MRT)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Terminal elimination rate constant (λz)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Time of the last quantifiable concentration [tlast Ae(0-last)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Cumulative fraction (%) of dose excreted unchanged into the urine from time zero to the last measured time point [fe(0-last)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Amount of analyte excreted into the urine from time t1 to t2 [Ae(t1-t2)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)]
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Renal clearance of drug from plasma, estimated by dividing Ae(0-t) by AUC(0-t) where the 0-t interval is the same for both Ae and AUC (CLR)
To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Apolipoprotein L1 (APOL1) concentrations and change from baseline
To assess the effect of SC SAD administrations of AZD2373 on plasma concentrations of APOL1 protein
Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2020 to primary completion in Aug 2021, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opemalirsen